|View printer-friendly version|
|May 17, 2006 1:45 p.m.|
|Teva Announces FDA Grants Approval of Azilect® (Rasagiline) for Parkinson's Disease|
Jerusalem, Israel, May 17, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for once-daily AZILECT® (rasagiline tablets) as a treatment for Parkinson's disease both as initial monotherapy in early Parkinson's disease patients and as adjunct therapy to levodopa in moderate-to-advanced stages of the disease. AZILECT® will become available in the U.S. within 8 to 10 weeks.